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Background. Primary hyperparathyroidism (PHPT) is associated with high cardiovascular morbidity, and the role of calcium and
parathyroid hormone is still controversial. Objective. To evaluate the prevalence and outcomes of metabolic syndrome, hyper-
tension, and some cardiovascular alterations in asymptomatic PHPT, and speciﬁc changes after successful parathyroidectomy.
Material and Methods. We examined 30 newly diagnosed PHPT patients (8 males, 22 females; mean age 56 ± 6yrs),30patients
with essential hypertension (EH) (9 males, 21 females; mean age 55 ± 4), and 30 normal subjects (NS) (9 males, 21 females:
mean age 55 ± 6). All groups underwent evaluation with ambulatory monitoring blood pressure, echocardiography, and color-
Doppler artery ultrasonography and were successively revaluated after one year from parathyroidectomy. Results. PHPT patients
presented a higher prevalence of metabolic syndrome (38%) with respect to EH (28%). Prevalence of hypertension in PHPT was
81%, and 57% presented altered circadian rhythm of blood pressure, with respect to EH (35%) and NS (15%). PHPT showed an
importantmyocardial andvascular remodelling.Duringfollow-upinPHPTpatients,wefoundsigniﬁcant reductionofprevalence
of metabolic syndrome, blood pressure, and “non-dipping phenomenon.” Conclusions. Cardiovascular and metabolic alterations
should be considered as added parameters in evaluation of patients with asymptomatic PHPT.
1.Introduction
Primary hyperparathyroidism (PHPT) is an endocrine dis-
ease characterized by hypercalcemia due to overproduction
ofparathyroidhormone(PTH),dependentonsingleordou-
ble adenoma (80–85%), hyperplasia (15–20%), and para-
thyroid carcinoma (<1%) [1–3].
The clinical presentation of PHPT shows geographic dif-
ferences, and this disease is accompanied by lack of clinically
apparent symptoms, with mild or no signs of complications
inasubstantial proportion ofindividuals [4–7].Thischronic
disease is associated with high cardiovascular morbidity
and mortality [8–11]. The asymptomatic form currently
accounts more than 80% of overall PHPT cases.
SomestudieshavesuggestedthatPHPTisassociatedwith
metabolic disorders such as impairment of glucose meta-
bolism, altered lipid proﬁle, hypertension, and structural
and functional alterations in cardiovascular system, whereas
is uncertain the exact role of calcium and/or PTH in the
development of cardiometabolic disorders [12–24].2 International Journal of Endocrinology
The aim of the present study was to investigate in a con-
secutive series of asymptomatic PHPT patients the preva-
lence of arterial hypertension, metabolic syndrome, and sub-
clinical cardiovascular organ damage, at diagnosis and after
successful parathyroidectomy.
2.MaterialsandMethods
Since January 2008 until October 2011, at the Depart-
ment Unit of Secondary Hypertension, University of Rome
“Sapienza”, Italy, we examined 30 consecutive newly diag-
nosed patients with asymptomatic PHPT (8 males, 22 femal-
es; mean age 56 ±6yrs).
The PHPT diagnosis was established according to labo-
ratory data characterized by the persistence of high levels of
total calcium, ionized calcium, and PTH. All patients under-
went neck ultrasonography (US) and/or Tc99m-Sesta MIBI
scintiscan imaging. We excluded familial form of PHPT, like
multiple endocrine neoplasia (MEN), type 1 or type 2A.
T h eP H P Ts u b j e c t sw e r ed e ﬁ n e d“ a s y m p t o m a t i c ”i f ,w i t h -
outspeciﬁclesionsofdisease,suchaskidneystonesandbone
lesions radiologically evident, were absent.
Oﬃce blood pressure (BP) was measured with a standard
aneroid manometer with subjects sitting for 5min, systolic
BP (SBP) was taken as the ﬁrst sound on deﬂation of the
cuﬀ (Korotkoﬀ phase I), and diastolic BP (DBP) was taken as
the complete disappearance of Korotkoﬀ sounds (phase V).
Hypertension was conﬁrmed by repeated BP measurements
of SBP > 140mmHg and DBP > 90mmHg [25].
Control groups consist of 30 patients with essential
hypertension (EH) (9 males, 21 females; mean age 55±4yrs)
and 30 normal subjects (NS) (9 males, 21 females; mean age
55±6yrs),whowerenotaﬀectedbyhypertension,metabolic
syndrome, diabetes mellitus, and cardiovascular diseases. In
all subjects, secondary hypertension was excluded on the
basis of biochemical, hormonal, and instrumental tests.
No patient had renal insuﬃciency (serum creatinine
level <1.3mg/dL), diabetes mellitus, thyroid dysfunctions,
or major cardiovascular disease. This study was performed
according to the Declaration of Helsinki II and approved by
the local Ethics Committee. All participant gave informed
consent.
2.1. Anthropometric Parameters. All patients underwent to
assessment of weight (kg), height (cm), body mass index
(BMI, expressed in kg/m2), waist circumference (WC, cm:
measured to a minimum of inspiration to the midpoint of
the line joining the last rib and the iliac crest).
2.2. Biochemistry. Biochemical variables were determined
after an overnight fast by anaerobic sampling, evaluating cal-
cium-phosphorus metabolism (total and ionized calcium,
phosphorus, total and ionized magnesium, alkaline phos-
phatase, parathyroid hormone (PTH), 25 (OH) vitamin D,
and alkaline phosphatase (ALP)), renal function (creatinine,
blood urea nitrogen, and serum electrolytes), and lipid
and glucose metabolisms (total cholesterol, HDL choles-
terol, LDL cholesterol, triglycerides, and blood fasting glu-
cose). Patients performed a 24-hour urine collection for
determination of urinary excretion of calcium and phospho-
rous. Ionized calcium was measured with a potentiometric
analyzer: the range of this method at pH 7.4 was 1.17–
1.33mmol/L. Intact serum PTH (i-PTH) was measured
using a radioimmunoassay method (RIA commercial kits;
Diasorin PTH, Still Water, MN, USA).
2.3. PHPT Diagnosis and Surgical Treatment. The diagnosis
and surgical treatment of asymptomatic PHPT patients
have been recently updated by international workshop [26].
Thepreoperativeimagingstudy(ultrasonography,computed
tomography, and MIBI scintigraphy), although not recom-
mended for diagnostic purposes, has been used for local-
ization and mini-invasively treatment, especially in patients
who have previously undergone parathyroid or other neck
surgery. Intraoperative PTH measurements were used to
limit duration of parathyroidectomy. Focused surgery was
performed by our specialist surgeon with high experience
in this kind of operation [27]. We enrolled PHPT patients
with histopathologically conﬁrmed single adenoma and lack
of recurrence after followup. We did not evaluate the gland
size of parathyroid adenomas.
2.4. Bone Mineral Densitometry (BMD). Bone mineral den-
sity (BMD) at lumbar spine (L1–L4) and femoral neck (FN)
was obtained in all patients using dual-energy X-ray absorp-
tiometry (DXA) using Hologic QDR-4500 device (Hologic,
Inc., Waltham, MA, USA) according to WHO recommen-
dations. The assessment of BMD was expressed as g/cm2
and as standard deviation from the mean peak bone mass
than healthy adults of the same sex (T-score). The diagno-
sis of osteoporosis was made in the case of T-score ≤−2.5,
and osteopenia if T-score was between −2.5/−1, normal
bone mass with superior T-score of −1[ 28]. Regarding the
precision of BMD evaluation, the coeﬃcient variation was
1% at the lumbar spine and 1.2% at femoral neck side.
2.5. Ambulatory Blood Pressure Monitoring (ABPM). ABPM
for 24h was performed by means of an oscillometric device
Space Labs 90207 (Space Labs Medical, Richmond, WA,
USA) which was set to measure BP for every 15min during
theday(from6:00to22:00hours)andevery30minduring
the night (from 22:00 to 6:00 hours). The deﬁnition of
“dipper” and “non-dipper” was established where night time
SBP and DBP decrease was >10% and <10%, respectively.
Subjects without a complete 24h BP measurement (14
diurnal and 7 nocturnal measurements) repeated the ABPM.
The length of hypertension was not evaluated in study
groups.
2.6. Metabolic Syndrome. Metabolic syndrome was deﬁned
according to Adult Treatment Panel III [29] criteria, and
its diagnosis required three or more of the following: (1)
waist circumference (WC) greater than 102cm in men and
greater than 88cm in women, (2) triglycerides of 150mg/dL
orhigher,(3)high-densitylipoprotein(HDL)cholesterolless
than 40mg/dL for men and less than 50mg/dL for women,
(4) fasting glucose of 100mg/dL or more, and (5) systolicInternational Journal of Endocrinology 3
BP of 130mmHg or more and diastolic BP of 85mmHg or
more.
2.7. Echocardiography. Echocardiography was carried out by
same physician operator (SS) in left patient lateral decubi-
tus by a Toshiba echocardiography equipment APLIO with a
multifrequency transducer, 2nd harmonic, and TDI imple-
mentation, with simultaneous continuous ECG monitor-
ing. Motion mode (M-mode) measurements were recorded
through the parasternal view following the recommenda-
tions of the American Society of Echocardiography.
Myocardial thickness and left ventricular (LV) diameter
at the end of diastole and at the end of systole were measured
in M-mode. Left ventricular mass (LVM) was indexed (i)
for height and surface area; LVM was determined from the
interventricular septum (IVS) and posterior wall thickness
(PWLV), diastolic diameters by use of the M-mode formula
of Troy. The relative LV wall thickness was calculated as the
sum of the interventricular and PW thickness divided by the
diastolic diameter. LV values were calculated according to
the Teicholz M-mode formula used to calculate the ejection
fraction (EF). Aortic (Ao) root diameter was measured at
diastolebytheleading-edge-to-leading-edgetechniqueatthe
maximal diameter of the sinuses of Valsalva.
Doppler echocardiographic parameters: early (E) and
late (A) mitral and tricuspidal velocities ratio (E/A ratio) iso-
volumetric relaxation time (IVRT). Right atrium (RA) and
leftatrium(LA)diameterswerealsomeasured.Leftventricu-
lar hypertrophy (LVH) was considered present, if the LVMi
exceeded 110g/m2 in women and 131g/m2 in man.
2.8. Ultrasound Evaluation of the Carotid Arterial Wall. The
carotid arteries were examined by ultrasound by same train-
ed operator (MC), and both carotid arteries (common caro-
tid, bifurcation, and internal carotid) were examined in
eachsubject;themeancarotidarteryintima-mediathickness
(IMT) was deﬁned as the overage of 36 IMT readings (com-
mon, bifurcation and internal carotid arteries, right and left
side, far and near wall, with three sampling points for seg-
ment). Plaques were deﬁned as a focal protrusion major of
50% of the surrounding wall. Arterial wall thickening was
deﬁnedasameancarotidIMT>0.90mm,anditisconsistent
with the deﬁnition of carotid wall thickening proposed in
the clinical guidelines for the management of arterial hyper-
tension issued by the European Society of Hypertension and
EuropeanSocietyofCardiology(ESH/ESC).Allsubjectsgave
their written consent after explanation of the nature and
purpose of the study.
2.9. Statistical Analysis. Statistical analysis was performed
with Sigmastat program (Jandel Corporation, USA). All data
are expressed as mean ± standard deviation (SD). The com-
parison between groups was performed using the Student t-
test for variables distributed in the normal way and by the
Mann-Whitney test for nonparametric variables. The study
of correlations between various parameters was performed
using the Spearman test and in case of multiple correla-
tions was performed multivariate analysis using Backward
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Figure 1: Prevalence of “non-dipping pattern” in all groups stud-
ied. NS: normal subjects; EH: patients with essential hypertension;
PHPT: patients with primary hyperparathyroidism. ∗P = 0.02
versus NS.
Stepwise Regression method. A P<0.05 was considered sta-
tistically signiﬁcant.
3. Results
Results of demographic, biochemical, and cardiovascular
parameters are reported in Table 1, We found no diﬀerences
in all groups for sex and mean age. As expected, we found
values of PTH more elevated in patients with PHPT than
in those of both control groups, EH and NS (P<0.001,
resp.). We observed no statistically signiﬁcative diﬀerences
regarding the prevalence of hypovitaminosis D (vitamin D <
20ng/mL) between PHPT patients and control groups
(PHPT: 25%; EH: 20%; NS: 19%).
Patients with PHPT and EH showed alterations of fast-
ing blood glucose, total cholesterol, LDL cholesterol, triglyc-
erides,anduricacidserumlevelscomparedtoNS(P<0.001,
resp.). Moreover, clinical blood pressure (SBP and DBP)
values were higher in EH and PHPT patients compared to
NS (P<0.001, resp.). However, only in PHPT patients, we
revealed higher heart rate (HR) with respect to EH and NS
(P<0.001, resp.). In PHPT, hypertension was present in
81% of patients.
The ABPM showed signiﬁcantly higher values of global-
SBP (G-SBP), diurnal-SBP (D-SBP) and global DBP (G-
DBP) in PHPT and EH patients compared to NS (Table 2).
No signiﬁcant diﬀerence were found for ABPM between
PHPT and EH patients. At diagnosis, 57% of PHPT patients
presented a nocturnal “non-dipping pattern” respect to 35%
of EH patients and 15% of NS (Figure 1). Moreover, the
correlation study revealed in PHPT patients, a positive
correlation between SBP and PTH levels (r = 0.512; P<
0.05) (Figure 2) The prevalence of metabolic syndrome
was present in 38% of PHPT and in 28% of EH patients
(Figure 3).
PHPT and EH patients showed an important cardiac
remodeling compared to NS, such as signiﬁcant increase of
theIVSi(10.7±0.9mmand11±0.9mmversus8.8±1.2mm,4 International Journal of Endocrinology
Table 1: Demographic, biochemical, calcium-phosphorus mineral metabolism, and bone mineral density in studied groups.
Age (yrs) Sex (M/F) BMI (kg/m2) WC (cm) SBP (mmHg) DBP (mmHg) HR (bpm)
PHPT (n.30) 54 ±12 8M/22 F 27.4 ±4.49 5 .7 ±11.8 144 ±10.2∗ 90.4 ±10.3∗ 75 ±6.4∗
EH (n.30) 55 ±59 M / 2 1 F 2 7 .1 ±2.39 0 ±3.5 135.3 ±5∗ 84.4 ±5∗ 71 ±8
NS (n.30) 55 ±69 M / 2 1 F 2 6 .1 ±2.19 85.7 ±2.19 129.3 ±47 8 .4 ±46 9 ±9
P ns ns ns ns
∗ <0.001 versus
NS
∗ <0.001 versus
NS
∗ <0.001
versus
EH-NS
Creatinine
(mg/dL)
Fasting blood
glucose (mg/dL) CT (mg/dL) LDL-C (mg/dL) HDL-C (mg/dL) TG (mg/dL) Uric acid
(mg/dL)
PHPT (n.30) 0.96 ±0.49 2 .6 ± 7.5∗ 227.4 ±26.2∗ 146 ±21.3∗ 54 ±6.2 135 ±21.7∗ 6.9 ±2.6∗
EH (n.30) 1.02 ±0.03 102.5 ± 14.5∗ 217 ±41.3∗ 133.7 ±36.4∗ 55.3 ±13.9 140.7 ±33.5∗ 5.07±2.1∗
NS (n.30) 0.94 ±0.38 3 .9 ±4 192 ±17.5 116.8 ±18.55 7 .4 ±7.49 4 .5 ±16.13 .6 ±1
P ns
∗0.001 versus
NS
∗0.001 versus
NS
∗0.001 versus
NS ns
∗0.001 versus
NS
∗0.001
versus NS
Calcium
(mg/dL) Ca++ (mmol/L) Phosphorous
(mg/dL) Mg++ (mmol/L) Ca Ur (mg/24h) PTH (pg/mL) ALP
(UI/L)
PHPT (n.30) 11.2 ±1.2∗ 1.51 ± 0.2∗ 2.73 ±0.8∗ 0.45 ±0.06∗ 352 ±177∗ 122 ±47.7∗ 154±74.6∗
EH (n.30) 9.8 ±0.21 .22 ±0.03 2.95 ±0.30 .53 ±0.03 170 ±18.33 2 ±5.3 112 ±57
NS (n.30) 9.4 ±0.31 .21 ±0.02 3.43 ±0.36 0.52 ±0.04 155 ±17.32 9 ±2.39 100 ±52
P
∗<0.001 versus
EH-NS
∗<0.001 versus
EH-NS
∗0.006 versus
EH-NS
∗0.006 versus
EH-NS
∗<0.001 versus
EH-NS
∗<0.001 versus
EH-NS
∗0.016
versus
EH-NS
BMD L1-L4
(gr/cm2)
BMD Fn
(gr/cm2)
PHPT (n.30) 0.870 ±0.15∗ 0.750 ± 0.14∗
EH (n.30) 0.980 ±0.10 .83 ±0.11
NS (n.30) 1 ±0.09 0.82 ±0.08
P
∗<0.001 versus
EH-NS
∗<0.001 versus
EH-NS
BMI:bodymassindex;WC:waistcircumference;SBP:systolicbloodpressure;DBP:diastolicbloodpressure;HR:heartrate;CT:totalcholesterol;LDL-C:low-
density cholesterol; HDL-C: high-density cholesterol; TG: triglycerides; ns: not signiﬁcative; Ca++: serum-ionized calcium; Mg++: serum-ionized magnesium;
Ca Ur: calcium urinary excretion in 24 hours; PTH: serum parathyroid hormone; ALP: serum phosphatase alkaline; BMD: bone mineral density at lumbar
spine (L1–L4) and femoral neck (Fn).
Table 2: Ambulatory blood pressure monitoring (ABPM) during 24 hours in studied groups.
SBP-G
(mmHg)
DBP-G
(mmHg) HR-G (bpm) SBP-D
(mmHg)
DBP-D
(mmHg)
HR-D
(bpm)
SBP-N
(mmHg)
DBP-N
(mmHg)
HR-N
(bpm)
PHPT (n.30) 126 ±18∗ 73 ± 21∗ 81 ± 10∗ 130 ± 18∗ 82 ± 10 85 ± 8.5∗ 117 ± 18 67±17 72 ± 8.5
EH (n.30) 131 ± 19∗ 82 ± 11∗ 75 ± 10 137 ± 15∗ 86 ± 11 78 ± 11 123 ± 18 74 ± 12 69 ± 10
NS (n.30) 116 ± 47 4 ± 57 5 ± 6 119 ± 47 7 ± 57 7 ± 7 109 ± 76 9 ± 66 9 ± 5
P
∗<0.001 versus
NS
∗<0.001 versus
NS
∗<0.002
versus
EH-NS
∗<0.001
versus NS ns
∗<0.004
versus
EH-NS
ns ns ns
SBP-G:globalsystolicbloodpressure;DBP-G:globaldiastolicbloodpressure;HR-G:globalheartrate;SBP-D:diurnalsystolicbloodpressure;DBP-D:diurnal
diastolic blood pressure; HR-D: diurnal heart rate; SBP-N: nocturnal systolic blood pressure; DBP-N: nocturnal diastolic blood pressure; HR-N: nocturnal
heart rate.
resp.; P<0.001), LVMi (182 ± 30.4mm and 183 ± 63mm
versus 125 ± 26mm, resp.; P<0.001), and LAi (37.5 ±
3.5mmand39± 3.8mmversus20.8 ± 2.4mm, resp.; P<
0.001) (Table 3). Moreover, 29.3% of PHPT patients showed
a calciﬁcation of the aorta, and 28.5% had an altered release
of the left ventricle (E/A < 1). In PHPT patients, we detected
a signiﬁcant negatively correlations between BMD at lumbar
spine (L1–L4) and femoral neck (Fn) with the dimension of
LAi (r =− 0.46, P<0.01; r =− 0.63, P<0.001, resp.)
(Figure 4).
PHPT and EH patients present an IMT of the common
carotidssigniﬁcantlygreaterthanNS(0.8±0.3mmand0.8±
0.1mmversus0.6±0.07, resp.; P = 0.05). Moreover, 9.7% of
PHPT patients had atherosclerotic plaques at arterial carotidInternational Journal of Endocrinology 5
Table 3: Echocardiographic parameters in studied groups.
IVSi (mm/m2) PWLVi
(mm/m2)
LV-DTDi
(mm/m2)
LV-DTSi
(mm/m2) LAi (mm/m2)E F ( % ) LVMi
(mm/m2) IMT (mm)
PHPT (n.30) 10.7 ±0.9∗ 10.4 ±1.4∗ 46 ±5.9∗ 30 ±2.4∗ 37.5 ±3.5∗ 59 ± 3.2 182 ±30.4∗ 0.8 ±0.3∗
EH (n.30) 11 ±0.9∗ 10.7 ±1.1∗ 48 ±3.9∗ 32 ±3.4∗ 39 ±3.8∗ 59 ± 3.3 183 ± 63∗ 0.8 ±0.1∗
NS (n.30) 8.8 ±1.28 .9 ±1.22 9 .3 ±1.91 8 .3 ± 1.92 0 .8 ±2.45 8 ± 2.5 125 ±26 0.6 ±0.07
P A-B versus C
∗<0.001 versus
NS
∗0.01 versus
NS
∗<0.001
versus NS
∗<0.001
versus NS
∗<0.001
versus NS ns
∗<0.001
versus NS
∗<0.05 versus
NS
IVSi: interventricle septum; PWLVi: posterior wall; LV-DTDi: telediastolic diameter of left ventricle; LV-DTSi: telesystolic diameter of left ventricle; LAi: left
atrium; EF: ejection fraction; LVMi: mass of left ventricle indexed; IMT: intima-media thickness.
Table 4
(a) Multiple regression analysis between interventricular septum (IVS) and
metabolic variables in PHPT patients.
Variables Coeﬃcient P value
Age (years) 0.0390 0.043
BMI (kg/m2) −0.0186 0.699
Calcium ionized (mmol/L) 7.288 0.012
PTH (pg/mL) 0.00357 0.453
Fasting blood glucose (mg/dL) 0.0657 0.056
Total cholesterol (mg/dL) 0.0188 0.889
LDL-cholesterol (mg/dL) −0.0242 0.121
Uric acid (mg/dL) −0.0732 0.630
Systolic blood pressure (mmHg) 0.00527 0.217
Diastolic blood pressure (mmHg) −0.0000196 0.368
(b) Multiple regression analysis between posterior wall of the left ventricle
(PWLV-i) and metabolic variables in PHPT patients.
Variables Coeﬃcient P value
Age (years) 0.0282 0.050
BMI (kg/m2) 0.0421 0.346
Calcium ionized (mmol/L) 5.183 0.048
PTH (pg/mL) 0.00598 0.374
Fasting blood glucose (mg/dL) 0.0455 0.211
Total cholesterol (mg/dL) 0.0197 0.241
LDL-cholesterol (mg/dL) −0.0249 0.657
Uric acid (mg/dL) 0.0734 0.635
Systolic blood pressure (mmHg) 0.00620 0.149
Diastolic blood pressure (mmHg) −0.0176 0.589
bulbs,withpositivecorrelationbetween24hurinarycalcium
excretion and IMT (r = 0.650, P<0.03).
In all PHPT patients, multivariate analysis showed that
serumcalciumalongwiththeageconstitutesanindependent
factorforcardiacremodelling,suchasincreaseoftheIVSand
PWLV (Tables 4(a) and 4(b)).
3.1. After Parathyroidectomy. All patients underwent mini-
invasive parathyroidectomy, with the detection of intraoper-
ative PTH levels. After a mean follow-up of 12 month (range
10–18 months), all PHPT patients had parathyroid adenoma
based on pathological examination, showing normalization
r = 0.512
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Figure 2: Linear correlation in PHPT patients between PTH levels
and systolic blood pressure values (SBP) (r = 0.512, P<0.05).
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Figure 3: Prevalence of arterial hypertension, “non-dipping pat-
tern,” and metabolic syndrome in PHPT patients before (PHPT
before) and after surgery (PHPT after). ∗P<0.05.
of serum calcium and PTH levels as normal urinary calcium
and phosphorous excretion (Table 5).
There was a signiﬁcant decrease in clinical SBP and DBP
(P<0.001 and P<0.002, resp.) and signiﬁcant reduction
of the SBP-G (126 ± 18mmHg versus 116 ± 18mmHg, P<
0.001), SBP-D (130 ± 18mmHg versus 119 ± 15mmHg,
P<0.05), HR-G (81 ± 10bpm versus 75 ± 10bpm, P<
0.02), and HR-D (85 ± 8.5mmHg versus 77 ± 6.9mmHg,6 International Journal of Endocrinology
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Figure 4: Linear correlation in PHPT patients between left atrium diameter (LAi) and bone mineral density (BMD) at lumbar spine (a)
(r =− 0.46; P<0.01) and femoral neck (b) (r =− 0.63; P<0.001).
Table 5: Demographic, biochemical, ABPM, echocardiographic, IMT parameters in PHPT patients before (PHPT pre) and after (PHPT
post) surgery.
WC (cm) SBP (mmHg) DBP (mmHg) HR (bpm) Glycaemia
(mg/dL)
CT
(mg/dL)
LDL-C
(mg/dL)
HDL-C
(mg/dL)
TG
(mg/dL)
PHPT pre
(n.30) 95.7 ± 12 144 ± 19.2 90.4 ±10.37 5 ± 9.4 92.6 ±7.5 227 ± 26 146.1 ± 42 54 ± 6.2 135 ± 22
PHPT post
(n.30) 95 ± 10.3 117 ± 19.2 83 ± 14.3 65 ± 8.1 87.9 ±10.2 209 ± 25 132 ± 23 57 ± 12 118 ± 35
P ns 0.001 0.002 ns ns ns ns ns ns
Calcium
(mg/dL)
Ca++
(mmol/L)
Phosphorous
(mg/dL)
Magnesium
(mg/dL)
Mg++
(mmol/L)
Ca Ur
(mg/24h)
PU r
(mg/24h)
PTH
(pg/mL)
ALP
(UI/L)
PHPT pre
(n.30) 11.2 ±1.21 .51 ±0.22 .73 ±0.81 .94 ±0.21 0.45 ±0.06 353 ±177 829 ±340 122 ±47 154 ±75
PHPT post
(n.30) 8.9 ±2.11 .2 ±0.08 3.3 ±0.76 1.77 ±0.33 0.51 ±0.07 126 ±96 578 ±277 50.9 ±22 106 ±80
P <0.001 <0.001 <0.001 ns 0.001 <0.001 0.003 <0.001 ns
SBP-G
(mmHg)
DBP-G
(mmHg) HR-G (bpm) SBP-D (mmHg) DBP-D
(mmHg)
HR-D
(bpm)
SBP-N
(mmHg)
DBP-N
(mmHg)
HR-N
(bpm)
PHPT pre
(n.30) 126 ±18 73 ±21 81 ±10 130 ±18 82 ±10 85 ±8.5 117 ±18 67 ±17 72 ±8
PHPT post
(n.30) 116 ±18 73 ±15 75 ±10 119 ±15 77 ±10 77 ±6.9 109 ±16 67 ±16 70 ±5
P 0.001 ns 0.002 0.001 ns <0.01 ns ns ns
IVSi
(mm/m2)
PWLVi
(mm/m2)
LV-DTDi
(mm/m2)
LV-DTSi
(mm/m2) LAi (mm/m2)E F ( % ) LVMi
(mm/m2) IMT (mm)
PHPT pre
(n.30) 11 ±0.91 0 ±1.44 6 ±5.93 0 ±2.43 7 .5 ±3.55 9 ±3.2 182 ±30 0.8 ±0.3
PHPT post
(n.30) 11 ±1.21 0 ±1.14 6 ±2.22 9 .6 ±3.23 7 .5 ±2.95 6 .8 ±5 176 ±32 0.7 ±0.2
P ns ns ns ns ns ns ns ns
WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; CT: total cholesterol; LDL-C: low-density cholesterol;
HDL-C: high-density cholesterol; TG: triglycerides; ns: not signiﬁcative; Ca++: serum-ionized calcium; Mg++: serum-ionized magnesium; Ca Ur: calcium
urinary excretion in 24 hours; P Ur: phosphorous urinary excretion in 24 hours; PTH: serum parathyroid hormone; ALP: serum phosphatase alkaline; SBP-
G: global systolic blood pressure; DBP-G: global diastolic blood pressure; HR-G: global heart rate; SBP-D: diurnal systolic blood pressure; DBP-D: diurnal
diastolic blood pressure; HR-D: diurnal heart rate; SBP-N: nocturnal systolic blood pressure; DBP-N: nocturnal diastolic blood pressure; HR-N: nocturnal
heart rate; IVSi: interventricle septum; PWLVi: posterior wall; LV-DTDi: telediastolic diameter of left ventricle; LV-DTSi: telesystolic diameter of left ventricle;
LAi: left atrium; EF: ejection fraction; LVMi: mass of left ventricle indexed; IMT: intima-media thickness.International Journal of Endocrinology 7
Table 6: Antihypertensive drugs taken by PHPT patients at baseline (before) and after 12 months from surgery.
AT1 receptor antagonists Ace inhibitor α-Blocker Diuretic Calcium antagonist β-Blocker
Before 42% 28.6% 9.5% 33% 19% 4.7%
After 33% 4.7% 9.5% 19% 14% 4.7%
−21% −83.5% — −42% −26% —
P<0.01). Moreover, we also showed signiﬁcant decrease of
“non-dipping pattern” (57% versus 42%; P<0.05).
As well as signiﬁcant reduction of blood pressure values
(decreased prevalence of hypertension from 81% to 62%),
we found a signiﬁcant decrease of mean number of antihy-
pertensive drugs (mean 1.7 versus 1.05; P<0.001), 15%
of patients did not take any antihypertensive drug, and 50%
patientstooklessnumberanddoseofantihypertensivedrugs
(Table 6). Thus, we found an overall reduction of global
cardiovascular risk factors in PHPT patients, such as lower
prevalence of metabolic syndrome (38% versus 28%).
Regarding echocardiography, in PHPT patients the car-
diac parameters did not decrease signiﬁcantly after 12
monthsfromsurgery,exceptthepercentageofE/Aratio(<1)
(28.5% versus 12%; P<0.05).
4. Discussion
PHPT is a common endocrine disorder, with typical bone
involvement represented by a reduced bone mass at skeletal
sites rich in cortical tissue [30], and clinical features of
hypercalcemia such as fatigue, anorexia, thirst, and polyuria
[31]. Asymptomatic subtype (without typical renal and bone
involvement) became more frequent over last four decades,
probably due to outline determination of serum calcium
levels. There is a general agreement that symptomatic PHPT
patients should undergo parathyroidectomy [32]. On the
other hand, an increased body of evidence showed diﬀerent
metabolic and cardiovascular alterations associated with
asymptomatic PHPT, argues in favor of enhanced risk of
cardiovascular disorders in this condition [23, 33], especially
ifthesepatientsdidnotundergoparathyroidectomy[34,35].
In particular, these metabolic alterations include insulin
resistance [36], diabetes mellitus [37], hyperlipemia [38],
arterial hypertension [14, 39, 40], and disorders associated
to adiposity, as metabolic syndrome [29]. In our study, we
found an higher prevalence of metabolic syndrome (38%) in
PHPT patients with respect to EH patients (28%). The pre-
valence of the metabolic syndrome in our PHPT patients
was very higher than reported in a general population with
demographic characteristics recruited in Italy [41]. These
data conﬁrmed our precedent study [42]. In particular, we
showed an high prevalence (29.8%) of metabolic syndrome
in PHPT patients, correlated with signiﬁcant alterations
of some fat adipokines, such as leptin and adiponectin.
Previous PHPT reports have suggested that common mech-
anisms are responsible for the development of the metabolic
syndrome and some studies examined these cardiometabolic
abnormalities in detail [43], showing correlations between
PTH and several variables (dyslipidemia, obesity, hyper-
tension, and insulin resistance) observed in the metabolic
syndrome, suggesting a role of PHT in development of
abnormalities seen in this condition. Indeed, reduction of
PTH levels after successful parathyroidectomy is associated
to decrease of blood pressure, fasting blood glucose, serum
triglycerides, and cholesterol, with reduction of the percent-
age of the metabolic syndrome (38% versus 28%, resp.).
Inourstudy,weexaminedtheremodellingofcardiacand
vascular structure in PHPT patients, compared to EH and
NS. In PHPT and EH patients, we showed an alteration of
the LVM, IVS, and carotid IMT. Moreover, 29.3% of PHPT
patients had a calciﬁcation of the aorta and 28.5% had an
alteredreleaseoftheleftventricle(E/Aratio<1).Precedently,
some studies have reported a decrease of E/A ratio, which
maybeasignofimpairedLVdiastolicfunction.Inparticular,
Almquist and coworkers revealed that 83% of the PHPT
patients have an E/A ratio less than 1 [44]. Dalberg et al.
reported lower E/A ratio among PHPT patients compared
to controls, but the blood pressure was signiﬁcantly higher
in these patients [45] ,w h i l es o m es t u d i e sh a v er e p o r t e dn o
diﬀerences between PHPT patients and controls with E/A
ratio [46].
The cause and detailed characteristics of cardiovascular
derangement in PHPT have been incompletely clariﬁed. The
high prevalence of LVH in PHPT patients has been attri-
buted, in part, to eﬀects of PTH and/or hypercalcemia [3].
In fact, it has been shown that PTH has a direct eﬀect on
cardiomyocytes through the activation of the kinase C-pro-
tein [47] with an increase of cellular protein mass. Moreover,
other authors suggest that the increase in cardiac mass could
be secondary to a higher incidence of arterial hypertension
in PHPT patients [35]; in patients recruited in the present
study, there is a large share of hypertensive patients. PHPT
is associated with increased risk of arterial hypertension,
and recent investigations have reported high blood pressure
in 56% and 80% of PHPT patients [48–50]. In particular,
Broulik et al. showed high prevalence (68.9%) of arterial
hypertension in PHPT patients, with signiﬁcant reduction
of clinical mean SBP and SDP values after successful para-
thyroidectomy [51]. Several studies have demonstrated that
hypertensive individuals with a “non-dipping” blood pres-
sure pattern show an increased frequency of target organ
damage, such as LVH and carotid IMT [52]. In the present
study, we revealed that 57% of PHPT patients presented
“non-dipping” blood pressure pattern with respect to 35%
of EH patients and 15% of NS. In PHPT patients, this
phenomenon was reduced after parathyroidectomy (38%).
During ABPM registration, in PHPT group, we found a
signiﬁcantly higher heart rate during 24 hours and daytime
registration with respect to EH and NS, signiﬁcantly reduced
after surgical treatment of PHPT.8 International Journal of Endocrinology
The increased risk of death observed in PHPT patients
could be referred to higher bioelectrical risk due to enhanced
sympathetic activity; in previous work, we investigated sym-
pathovagal balance (heart rate variability and QT parame-
ters)inasymptomaticPHPTpatientscomparedtoNS,show-
ing in PHPT enhanced sympathetic tone (shorter QTc inter-
val, higher QTc dispersion, and lack of physiological adap-
tation of QT length to R-R interval), restored after parathy-
roidectomy.Moreover,Hysingetal.havesuggestedthatslight
increase of ionized calcium was associated to higher heart
rate probably due to autonomic nervous system hyperac-
tivity [53]. These ﬁndings conﬁrmed increased bioelectrical
risk to life-threatening arrhythmias in PHPT patients and
bioelectrical instability induced by hypercalcemia, gradually
reduced after parathyroidectomy [16, 17].
Serum calcium could be implicated in the pathogenesis
of arterial hypertension in PHPT [54]. Some authors sug-
gested that PHPT increases calcium inﬂux into the cell and,
consequently, its vasoconstriction. Previously, we reported
a positive correlation between serum-ionized calcium and
bloodpressureinPHPTpatients,suggestingthattheincrease
of serum-ionized calcium may be an independent factor of
peripheral resistance elevation [14]. In the present study, we
revealed, in PHPT patients, a positive correlation between
SBP and PTH values before parathyroidectomy (Figure 2).
These results are similar to data reported by Farahnak et al.
[55] that showed, in the PHPT group, SBP values were cor-
related to the levels of PTH and calcium, signiﬁcantly higher
comparedtocontrols,anddecreasedaftersuccessfulparathy-
roidectomy. However, the LVH in PHPT may be related
to hypercalcemia secondary autonomous overproduction of
PTH. This hypothesis is supported, in part, by our results.
In fact, in PHPT patients at the multiple regression analysis,
the IVS and PWLV are correlated only with serum-ionized
calcium and age.
Inthis study, carotidIMT is increased withrespectto NS,
and positively correlated with the urinary calcium excretion.
These data extended and conﬁrmed other results reported in
the literature [56].
Finally, in our study, another important result found is
therelationbetweenBMD,speciﬁctargetofPHPT,andsome
echocardiographic parameters, typical feature of organ dam-
age due to cardiovascular disease and metabolic disorders.
In fact, we showed negative correlations between BMD
values (at lumbar and femoral sites) and LA diameter. Left
atrial function has a large contribution in left ventricular
diastolicfunction.Increasedatrialresponsetoearly-stageleft
ventricular ﬁlling impairment is characterized by augment-
ed reservoir and pump functions, according to a Starling
mechanism, which becomes hardly eﬀective at end-stage
ventricular dysfunction when the limits of the atrial preload
reserve are reached. When left ventricular ﬁlling pressure
was increased, the E/A ratio increases, indicating a ﬁlling
shift towards early diastole. Signiﬁcant changes in left atrium
on diastolic function that we have observed in our PHPT
patients may contribute to failing left ventricular ﬁlling and
itself may undergo failure. In our patients, we found a signi-
ﬁcant reduction of E/A ratio after successful parathyroidec-
tomy.
Bone densitometry is an important component in the
evaluation of the bone metabolism in PHPT patients,
because it has more sensitivity than conventional radio-
grams. In PHPT, skeletal compromise is demonstrated by
reduced BMD values (osteopenia or osteoporosis), evident
especially at the cortical bone (i.e., femoral). There is a cross-
sectional association between BMD loss and aortic calci-
ﬁcation, carotid plaques, IMT, and coronary calciﬁcation
[57, 58]. In our study, 29.3% of PHPT patients showed a
calciﬁcation of aorta. The mineral within calciﬁed athero-
sclerosis plaques is hydroxyapatite, the same mineral as in
bone and matrix vesicles. Speciﬁc factors and protein crucial
to bone function are also present in atherosclerotic lesions.
The vascular calciﬁcation of the aorta was showed great-
er in patients with the amount of bone loss, and the progres-
sion of calciﬁcation is associated with increased bone loss in
women during menopause [59–61]. Probably, the mobiliza-
tion of calcium from the skeleton in PHPT may be responsi-
ble for its deposition in the atherosclerotic plaque and sever-
al mechanisms may explain this association, especially
regarding the role of PTH. The increment of PTH could be
responsible for a decrease in cortical bone and for an incre-
ment in cardiovascular risk too.
5. Conclusions
Signiﬁcant ﬁndings in our asymptomatic PHPT patients are
as follow: (1) about 38% of patients presented a metabolic
syndrome as deﬁned by ATP III criteria; (2) high proportion
of PHPT patients was hypertensive, with altered circadian
rhythm of blood pressure; (3) asymptomatic PHPT is asso-
ciated with cardiovascular manifestations, such as LVH and
increased carotid intima-media thickness, subclinical pre-
dictors of cardiac and cerebrovascular events; (4) relation
between BMD (at lumbar and femoral site) and some echo-
cardiographic parameters (LA) is evident; (5) parathyroidec-
tomysigniﬁcantlyreducesbloodpressureassociatedto“non-
dipping phenomenon” and metabolic syndrome.
Thesemetabolicandcardiovascularalterationsshouldbe
considered as added parameters in therapeutic evaluation of
patients with asymptomatic PHPT. Other studies are neces-
sary in order to fully establish the indications towards para-
thyroidectomy in asymptomatic PHPT patients.
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